Exdensur™ (depemokimab-ulaa) - CAM 970HB
Background
Exdensur is an interleukin-5 (IL-5) antagonist monoclonal antibody indicated as add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients 12 years of age and older. It is not indicated for the treatment of acute bronchospasm or status asthmaticus.
Policy (Criteria)
Coverage of these drugs is provided when the criteria below is met and for non-preferred products there has been a trial and failure of TWO preferred therapy.
Initial Authorization Criteria
Exdensur may be considered medically necessary when all of the following criteria are met:
1. Diagnosis of severe asthma with an eosinophilic phenotype
2. Patient is 12 years of age or older
3. Asthma remains inadequately controlled despite optimized standard therapy, as evidenced by one of the following:
- Two or more asthma exacerbations requiring systemic corticosteroids within the previous 12 months
- One or more asthma-related hospitalizations or emergency department visits within the previous 12 months
- Persistent poor symptom control despite optimized maintenance therapy
4. Patient is receiving optimized controller therapy, including:
- Medium- to high-dose inhaled corticosteroid (ICS)
- At least one additional controller medication (e.g., long-acting beta2-agonist [LABA], leukotriene receptor antagonist, long-acting muscarinic antagonist) unless contraindicated or not tolerated
5. Evidence of eosinophilic inflammation demonstrated by one of the following:
- Blood eosinophil count ≥150 cells/mcL within the past 6 weeks
- Blood eosinophil count ≥300 cells/mcL within the past 12 months
- Other specialist-documented evidence of eosinophilic asthma
6. Prescribed by or in consultation with one of the following:
- Allergist/Immunologist
- Pulmonologist
- Physician experienced in the management of severe asthma
7. Dose does not exceed:
- 100 mg administered subcutaneously once every 6 months
Authorization Duration: 6 months
Reauthorization Criteria
Exdensur may be reauthorized when all of the following criteria are met:
1. Documentation of positive clinical response to therapy
Examples include one or more of the following:
- Reduction in asthma exacerbations from baseline
- Reduction in oral corticosteroid requirements
- Improvement in Asthma Control Test (ACT) score
- Improvement in pulmonary function (e.g., FEV1)
- Reduction in asthma-related emergency department visits or hospitalizations
- Improvement in symptom control and quality of life
2. Patient continues to receive maintenance asthma therapy as clinically appropriate
3. Prescribed by or in consultation with an allergist/immunologist, pulmonologist, or severe asthma specialist
4. Dose does not exceed:
- 100 mg subcutaneously once every 6 months
Authorization Duration: 12 months
References
- EXDENSUR (depemokimab-ulaa) Prescribing Information. GlaxoSmithKline. Revised 2026. turn13search5
- U.S. Food and Drug Administration. EXDENSUR Highlights of Prescribing Information. 2025. turn13search1
- U.S. Food and Drug Administration. Drug Trials Snapsho: EXDENSUR. December 2025. turn13search6
- GlaxoSmithKline. Exdensur (depemokimab) Approved by U.. FDA for Severe Asthma. December 16, 2025. turn13search2
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Current version.
Coding Section
| Code |
Number |
Description |
| HCPCS |
J2361 |
Injection, depemokimab-ulaa, 1 mg |
| CPT |
96372 |
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); SC or IM |
|
|
96401 |
Chemotherapy administration, SC or IM; non-hormonal anti-neoplastic |
| ICD-10 |
J45.50 |
Severe persistent asthma, uncomplicated |
|
|
J45.51 |
Severe persistent asthma with (acute) exacerbations. X=0 uncomplicated, X=1 with exacerbations |
|
|
J82.83 |
Eosinophilic asthma |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |